GPT and metabolic dysfunction-associated steatohepatitis: A recent study demonstrated that 2 years of UDCA treatment effectively reduced liver dysfunction in Indian patients with NAFLD [11] and a high dose of UDCA (H-UDCA) reduced alanine aminotransferase (ALT) levels in patients with non-alcoholic steatohepatitis (NASH), suggesting numerous hepatoprotective effects of the drug [12].